Defunct Company
Total Trials
4
As Lead Sponsor
As Collaborator
0
Total Enrollment
521
NCT01493960
The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients
Phase: Phase 3
Role: Lead Sponsor
Start: Dec 31, 2011
Completion: Mar 31, 2014
NCT03178669
The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis
Phase: Phase 2
Start: Jun 21, 2017
Completion: Aug 30, 2019
NCT05404074
Pharmacokinetics of Cobitolimod Enemas in Participants With Active Ulcerative Colitis
Phase: Phase 1
Start: Nov 22, 2021
Completion: Oct 30, 2022
NCT04985968
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
Start: Nov 24, 2021
Completion: Dec 20, 2023